The relationship between sarcopenia and systemic inflammatory response for cancer cachexia in small cell lung cancer

PLoS ONE

Volumn 11, Issue 8, 2016, Pages

  Kim, Eun Young ^a   Kim, Young Saing ^a   Seo, Ja Young ^a   Park, Inkeun ^a   Ahn, Hee Kyung ^a   Jeong, Yu Mi ^a   Kim, Jeong Ho ^a   Kim, Nambeom ^a  

^a Gachon University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; LACTATE DEHYDROGENASE; BIOLOGICAL MARKER; SERUM ALBUMIN;

AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BODY MASS; BODY WEIGHT; CACHEXIA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MUSCLE INDEX; MUSCLE MASS; NEUTROPHIL LYMPHOCYTE RATIO; PERFORMANCE; PHYSICAL PARAMETERS; PREVALENCE; SARCOPENIA; SEX DIFFERENCE; SMALL CELL LUNG CANCER; SMOKING; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THIRD LUMBAR VERTEBRA; BLOOD; COMPLICATION; DIAGNOSTIC IMAGING; LUNG TUMOR; MIDDLE AGED; X-RAY COMPUTED TOMOGRAPHY;

AGED; BIOMARKERS; C-REACTIVE PROTEIN; CACHEXIA; FEMALE; HUMANS; LEUKOCYTE COUNT; LUNG NEOPLASMS; MALE; MIDDLE AGED; SARCOPENIA; SERUM ALBUMIN; SMALL CELL LUNG CARCINOMA; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84985037172     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0161125     Document Type: Article

References (26)

1. Fruh M, De Ruysscher D, Popat S, Crino L, Peters S, Felip E, et al. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24 Suppl 6: vi99-105. doi: 10.1093/annonc/mdt178 PMID: 23813929
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65: 87-108. doi: 10.3322/caac.21262 PMID: 25651787
3. Zhou T, Hong S, Hu Z, Hou X, Huang Y, Zhao H, et al. A systemic inflammation-based prognostic scores (mGPS) predicts overall survival of patients with small-cell lung cancer. Tumour Biol. 2015; 36: 337-343. doi: 10.1007/s13277-014-2623-4 PMID: 25256672
4. Kim EY, Kim YS, Park I, Ahn HK, Cho EK, Jeong YM. Prognostic Significance of CT-Determined Sarco-peniain Patients with Small-Cell Lung Cancer. J Thorac Oncol. 2015; 10:1795-1799. doi: 10.1097/JTO.0000000000000690 PMID: 26484630
5. Yang CW, Li CI, Li TC, Liu CS, Lin CH, Lin WY, et al. Association of Sarcopenic Obesity with Higher Serum High-Sensitivity C-Reactive Protein Levels in Chinese Older Males-A Community-Based Study (Taichung Community Health Study-Elderly, TCHS-E). PLoS One. 2015; 10: e0132908. doi: 10. 1371/journal.pone.0132908 PMID: 26177029
6. Schaap LA, Pluijm SM, Deeg DJ, Visser M. Inflammatory markers and loss of muscle mass (sarcope-nia) and strength. Am J Med. 2006; 119: 526e529-517.
7. Richards CH, Roxburgh CS, MacMillan MT, Isswiasi S, Robertson EG, Guthrie GK, et al. The relationships between body composition and the systemic inflammatory response in patients with primary operable colorectal cancer. PLoS One. 2012; 7: e41883. doi: 10.1371/journal.pone.0041883 PMID: 22870258
8. Consultation WHOE. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004; 363:157-163. PMID: 14726171
9. Kalemkerian GP, Gadgeel SM. Modern staging of small cell lung cancer. J Natl Compr Canc Netw. 2013; 11: 99-104. PMID: 23307985
10. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003; 89:1028-1030. PMID: 12966420
11. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res. 2006; 4: 221-233. PMID: 16603636
12. Azad N, Rojanasakul Y, Vallyathan V. Inflammation and lung cancer: roles of reactive oxygen/nitrogen species. J Toxicol Environ Health B Crit Rev. 2008; 11:1-15. doi: 10.1080/10937400701436460 PMID: 18176884
13. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O'Reilly DS, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer. 2011; 47: 2633-2641. doi: 10.1016/j.ejca.2011.03.028 PMID: 21724383
14. Proctor MJ, Morrison DS, Talwar D, Balmer SM, O'Reilly DS, Foulis AK, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer. 2011; 104: 726-734. doi: 10.1038/sj.bjc.6606087 PMID: 21266974
15. Shafique K, Proctor MJ, McMillan DC, Qureshi K, Leung H, Morrison DS. Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study. Prostate Cancer Prostatic Dis. 2012; 15:195-201. doi: 10.1038/pcan.2011.60 PMID: 22343838
16. He X, Zhou T, Yang Y, Hong S, Zhan J, Hu Z, et al. Advanced Lung Cancer Inflammation Index, a New Prognostic Score, Predicts Outcome in Patients With Small-Cell Lung Cancer. Clin Lung Cancer. 2015; 16: e165-171. doi: 10.1016/j.cllc.2015.03.005 PMID: 25922292
17. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011; 12: 489-495. doi: 10.1016/S1470-2045(10)70218-7 PMID: 21296615
18. Fearon KC, Voss AC, Hustead DS, Cancer Cachexia Study G. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr. 2006; 83:1345-1350. PMID: 16762946
19. Morley JE, Thomas DR, Wilson MM. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr. 2006; 83: 735-743. PMID: 16600922
20. Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013; 31:1539-1547. doi: 10.1200/JCO.2012.45.2722 PMID: 23530101
21. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008; 9: 629-635. doi: 10.1016/S1470-2045(08) 70153-0 PMID: 18539529
22. Argiles JM, Busquets S, Lopez-Soriano FJ.The pivotal role of cytokines in muscle wasting during cancer. Int J Biochem Cell Biol. 2005; 37:1609-1619. PMID: 15878837
23. Sarhill N, Mahmoud F, Walsh D, Nelson KA, Komurcu S, Davis M, et al. Evaluation of nutritional status in advanced metastatic cancer. Support Care Cancer. 2003; 11: 652-659. PMID: 12920623
24. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009; 12: 223-226. doi: 10.1097/MCO.0b013e32832a7902 PMID: 19318937
25. Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (1985). 2004; 97: 2333-2338.
26. Collins J, Noble S, Chester J, Coles B, Byrne A. The assessment and impact of sarcopenia in lung cancer: a systematic literature review. BMJ Open. 2014; 4: e003697. doi: 10.1136/bmjopen-2013-003697 PMID: 24384894